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Abstract
Background: Ovarian cancer stem cells (OCSCs) contribute to the poor prognosis of ovarian cancer. Involvement of
the androgen receptor (AR) in the malignant behaviors of other tumors has been reported. However, whether AR
associates with Nanog (a stem cell marker) and participates in OCSC functions remain unclear. In this study, we
investigated the interaction of Nanog with AR and examined whether this interaction induced stem-like properties
in ovarian cancer cells.
Methods: AR and Nanog expression in ovarian tumors was evaluated. Using the CRISPR/Cas9 system, we
constructed a Nanog green fluorescent protein (GFP) marker cell model to investigate the expression and
co-localization of Nanog and AR. Then, we examined the effect of androgen on the Nanog promoter in ovarian
cancer cell lines (A2780 and SKOV3). After androgen or anti-androgen treatment, cell proliferation, migration,
sphere formation, colony formation and tumorigenesis were assessed in vitro and in vivo.
Results: Both AR and Nanog expression were obviously high in ovarian tumors. Our results showed that Nanog
expression was correlated with AR expression. The androgen 5α-dihydrotestosterone (DHT) activated Nanog
promoter transcription. Meanwhile, Nanog GFP-positive cells treated with DHT exhibited higher levels of
proliferation, migration, sphere formation and colony formation. We also observed that the tumorigenesis of Nanog
GFP-positive cells was significantly higher than that of the GFP-negative cells. Xenografts of Nanog GFP-positive
cells showed significant differences when treated with androgen or anti-androgen drugs in vivo.
Conclusions: The interaction of Nanog with the AR signaling axis might induce or contribute to OCSC regulation.
In addition, androgen might promote stemness characteristics in ovarian cancer cells by activating the Nanog
promoter. This finding merits further study because it may provide a new understanding of OCSC regulation from a
hormone perspective and lead to the reevaluation of stem cell therapy for ovarian cancer.
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Background
Ovarian cancer is a lethal tumor in women worldwide,
with the highest mortality rate among gynecological
malignancies, and its 5-year survival rate is 30–40%
depending on tumor stage [1, 2]. Although many
improvements in surgical techniques and adjuvant ther-
apies have been made, the survival rate of ovarian cancer
patients has shown little improvement. The poor prog-
nosis of this malignancy is largely due to late detection,
chemoresistance, and a lack of targeted therapies for ad-
vanced and recurrent cases [2]. Evidence from epidemio-
logical and scientific studies has shown that hormones
play important roles in ovarian tumorigenesis and
progression [3]. Androgen receptor (AR) is located on
the X chromosome and is expressed in a diverse range
of normal and cancer tissues. AR binds to its native lig-
and, 5α-dihydrotestosterone (DHT), with strong affinity
in the nucleus. AR dimers bind to androgen response el-
ements (AREs) in the promoter region of target genes
[4]. AR has biological actions in both health and disease
and participates in both normal physiological processes
and pathological conditions. Several studies have shown
that AR is involved in the progression of numerous
malignancies, including prostate, bladder, liver, kidney
and lung cancers [5, 6]. In recent years, the relationship
between ovarian cancer and the AR signaling axis has
become a popular topic of research because polycystic
ovary syndrome and obesity are associated with a high
risk of ovarian cance [7, 8]. Meanwhile, emerging evi-
dence has indicated that AR is frequently expressed in
various ovarian cancer subtypes, especially epithelial
ovarian cancer, and its high expression is associated with
a poor prognosis [9–13]. The AR signaling axis pro-
motes the proliferation, migration and invasion of
ovarian cancer cells in vitro and in vivo and interacts
with many key signaling components, including the IL-
6/IL-8 and EGFR pathways [10, 14]. Nevertheless, the
mechanisms by which androgen and AR influence
cancer cell growth are complex. Additionally, AR may
stimulate cancer development and progression possibly
by expanding the population of cancer stem cells (CSCs).
CSCs are specific population of cancer cells that are
responsible for tumor initiation, drug resistance and me-
tastasis. However, the impact of AR has not been widely
pursued in ovarian cancer, and to date, the precise roles
of AR and CSCs in ovarian cancer are not fully
understood.
There is good evidence to support the view that most
human tumors harbor CSCs and that these CSCs pos-
sess the biological characteristics of normal stem cells.
CSCs also possess high self-renewal, extensive prolifera-
tive and strong tumorigenic capacities, and they are the
initiating cells in tumor progression, recurrence and che-
moresistance [15, 16]. CSCs are able to persist in tumors
and survive under nutrient starvation conditions [17].
Over the last few decades, a number of studies have
identified CSCs in human ovarian cancer cells. The de-
velopment and progression of ovarian cancer is fueled
and sustained by these undifferentiated CSCs. Indeed,
ovarian CSCs may be responsible for tumor growth,
peritoneal metastasis, chemoresistance and relapse.
Because CSCs can potentially arise from oncogenic
reprogramming and the dynamic nature of cancer cells,
identification of stem cell-related and self-renewal mole-
cules is expected to lead to novel therapeutic targets for
cancer [18].
In terms of CSC markers, Nanog has been identified
as a molecule that maintains CSC pluripotency and self-
renewal capability [19]. Nanog, Oct4 and Sox2 are
considered pluripotent genes and stem cell markers.
Nanog is a nuclear transcription factor that plays a
crucial role in pluripotent cells by maintaining their
embryonic stem-like properties and in cancer cells by
promoting carcinogenesis and reprogramming regulation
[20]. Many studies have indicated that Nanog is
expressed in a variety of cancers, and its expression is
correlated with poor survival [21]. Therefore, Nanog can
promotes CSC properties and characteristics, and such
potentially pluripotent “stem-like” cells may have an
impact on tumorigenesis and progression [22]. Further-
more, Nanog is highly expressed in ovarian cancer tis-
sues. Nanog overexpression in high-grade serous ovarian
cancer is significantly associated with increased che-
moresistance and poor survival. Although Nanog might
function as a stem cell-associated gene involved in
ovarian cancer tumorigenesis and prognosis [23, 24], the
regulation of Nanog in ovarian cancer is not well
understood.
Several signaling pathways that have been identified in
CSCs appear to be important for maintenance of the
CSC phenotype, and the participation of Nanog is a key
factor [25, 26]. Meanwhile, AR has been implicated as a
“molecular switch” that functions by coordinating and
regulating the expression of the stem cell network. AREs
contain the Nanog promoter. Thus, AR might regulate
the Nanog pathway to promote the stem-like differenti-
ation, proliferation and migration of some cancer cell
types [27, 28]. In addition, our previous study confirmed
that Nanog is associated with androgen/AR and plays an
important role in the regulation of stemness in liver
cancer cells [29]. However, these mechanisms remain
unclear in ovarian cancer.
Therefore, in this study, we conducted an investigation
to determine whether the AR signaling axis regulates
Nanog and promotes stem-like differentiation and
proliferation in ovarian cancer cells. The Clustered
Regularly Interspaced Short Palindromic Repeats/protein
9 (CRISPR/Cas9) system is a simple and efficient
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genome-editing tool that can be applied to various cell
types. We used the CRISPR/Cas9 system to target
Nanog and inserted an endogenous green fluorescent
protein (GFP) marker. With the CRISPR/Cas9 system,
the GFP marker can directly and accurately reflect
Nanog expression. Based on CRISPR/Cas9 technology,
we constructed a stable and reliable cell marker model
that avoids the genomic instability induced by integration
of indirect genetic markers via virus vectors and the disad-
vantages of markers that decay over time. Hence, this
approach is an efficient and stable method to examine
how the androgen signaling axis regulates Nanog in ovar-
ian cancer (Research model, Additional file 1: Figure S1).
We hope to explore new treatment strategies or drug tar-
gets for ovarian cancer treatment using this technology.
Methods
Tissue samples and cell culture conditions
Ovarian cancer samples were collected from patients
with primary ovarian cancer at the Department of Ob-
stetrics and Gynecology. According to the protocols, all
patients signed informed consent forms. This study was
approved by the Institutional Review Board of Southwest
Hospital, Third Military Medical University. The samples
were first diagnosed by a pathologist. In total, 14 fresh
samples were used for western blotting experiments: 7
were from epithelial serious ovarian cancer (stage III),
and 7 were from normal ovaries. In addition, 2 epithelial
serious ovarian tumors and 2 normal ovaries were used
for immunohistochemistry experiments.
The human ovarian cancer SKOV3 and A2780 cell
lines were purchased from the Shanghai Cell Collection.
Cells were cultured in Gibco’s modified 1640 medium
containing 10% fetal bovine serum (Gibco, NE), with
100 U/ml of penicillin sodium and 100 mg/ml of
streptomycin sulfate (HyClone, AUS), at 37 °C in a 5%
CO2 humidified atmosphere.
Endogenous Nanog labeling of ovarian cells with the
CRISPR/Cas9 system
The procedures for Nanog labeling via the CRISPR/Cas9
system were as follows (Flow chart, Additional file 1:
Figure S2): The CRISPR/Cas9 plasmids, including PX330,
were obtained from Addgene (USA), and Nanog-gRNA
was designed first. Next, PX330 was digested with BbSI
(New England Biolabs, UK), and Nanog-gRNA was
inserted into PX330 with T4 ligase (Promega, USA). After-
wards, the plasmids were used to transform Escherichia
coli for expansion and then extracted for Sanger sequen-
cing. The homologous arms of the Nanog termination
codon were amplified from human genomic DNA by
KOD FX (TOYOBO, JPN), joined with 2A-GFP using the
Gibson clone and cloned into a pMD19-T simple vector
(Takara, JPN). The constructed vectors were amplified,
and 2A oligodeoxynucleotide (2A-up/2A-down)/GFP
sequences were synthesized and annealed before use.
Then, all of these fragments were added to Gibson clone
buffer (New England Biolabs, UK) to connect into loops
and were used to transform competent Escherichia coli.
Endonuclease enzyme digestion and T7E1 assays were
performed as described previously. Then, the obtained
products were confirmed by Sanger sequencing and PCR
(Additional file 1: Figure S3, Additional file 1: Figure S4,
Additional file 1: Figure S5). Therefore, we used the
CRISPR/Cas9 system to label Nanog with GFP. The
Nanog-2A-GFP PCR primers are listed in the Additional
file 1: Table S1.
Cell transfection
Cells were cultured for transfection in 24-well plates.
When the cells reached approximately 70–80% con-
fluence, they were transfected with 0.25 μg of PX330-
Nanog-gRNA plasmid and/or 0.15 μg of the Nanog-
2A-GFP homogeneous arm vector with Effectene
transfection reagent (Qiagen, GER). After 72 h, GFP
fluorescence was examined, and cells were sorted.
Fluorescence-activated cell sorting
All transfected cells stably expressing GFP were sorted
with a FACSAria II cell sorter (BD Biosciences, USA).
Individual SKOV3 or A2780 cells with GFP expression
were seeded into 96-well plates for expansion, and then
labeled GFP (+) cells were verified by Sanger sequencing.
Single clones of SKOV3 + 5 or A2780 + 20 GFP (+) cells
and GFP (−) cells were cultured and passaged for further
studies.
RNA extraction and real-time qPCR analysis
Total RNA was extracted using an Eastep Super RNA
extraction kit (Promega, USA), and then, 1 μg of RNA
was converted to cDNA (reaction system 10 μl) with an
Advantage® RT-for-PCR kit (Takara, JPN). After 2 μl of
cDNA was mixed with SYBR Green (Bio-Rad Laborator-
ies Ltd., USA), quantitative real-time qPCR (RT-qPCR)
(reaction system 20 μl) was performed using a CFX96™
Real-Time system (Bio-Rad). GAPDH was used as the
internal control. Then, we calculated the mRNA tran-
script abundance relative to that of GAPDH. All experi-
ments were performed in triplicate. RT-qPCR primers
are listed in the Additional file 1: Table S1.
Western blotting analysis
For protein extraction, the tissues were first ground, and
then protein was extracted with tissue lysis buffer
(Thermo Fisher Scientific, USA). Cells were washed with
ice-cold PBS and lysed with cell lysis buffer. Whole-cell
lysates were collected from 1 × 106 cells. Protein
concentration was measured with a BCA protein assay
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kit (Beyotime, China). Western blotting assays were
performed as described previously. Briefly, 50 μg of
protein was loaded. The primary antibodies (1:1000) were
as follows: anti-Nanog (Cell Signaling Technology, USA),
anti-AR (N-20, Santa Cruz Biotechnology, USA), anti-
Oct4 (Abcam, UK), anti-Sox2 (Abcam, UK) and anti-
GAPDH (Cell Signaling Technology, USA). The secondary
antibody was diluted 1:3000. All antibodies were used at
the dilution recommended by the manufacturer.
Immunofluorescence analysis
Cells were grown in 24-well plates that were preloaded
with glass slides and cultured for 12 h. Then, the cells
were fixed with 4% paraformaldehyde for 30 min and
permeabilized with 0.3% Triton (Sigma Aldrich, USA)
for 10 min. After blocking with 10% BSA (Sigma Al-
drich, USA), the slides were incubated with primary
antibodies, namely, anti-Nanog (1:200) and anti-AR (1:
1000), for 16 h at 4 °C and then with the Alexa Fluor®
568-conjugated secondary antibody (1:1000) (Thermo
Fisher Scientific, USA) for 1 h at room temperature. The
slides were treated with DAPI (1:1000) for 15 min and
mounted with 40% glycerin before examination. Immuno-
fluorescence was detected with a confocal microscope
(Carl Zeiss Jena. JER) using the following parameters:
objective, 40×; scan mode, 1024 × 1024; and a scan time of
6.25 s.
Hormone treatment
DHT and ASC-J9 were used as the drugs for hormone
treatments. The drugs concentrations used were based
on our previous study [29]: DHT 10 nM and ASC-J9
5 μM. Cell viability was tested using an MTS Cell Prolif-
eration Assay kit (Promega, USA). Cells were seeded in
96-well plates at 1 × l04 cells/well, cultured for 24 h, and
then treated with 10 nM DHT (Dr. Ehrenstorfer GmbH,
GER) and/or 5 μM dimethylcurcumin (ASC-J9)
(MedChem Express, USA). Dimethyl sulfoxide (DMSO)
served as the vehicle control. After further incubation
for 24 and 48 h, MTT reagent (5 mg/l) was added to
each well, and the cells were further incubated for 4 h.
The number of viable cells was calculated relative to the
appropriate controls. The mean ± SD values from three
independent experiments are shown.
For hormone treatments, cultured cells were washed
and placed into serum-free medium for 24 h. Then,
10 nM DHT or 5 μM ASC-J9 dissolved in DMSO was
added into the medium. The cells were divided into
three groups: DHT, DHT +ASC-J9 and DMSO and were
harvested after 24 h.
Luciferase reporter gene and lentivirus vector assay
Luciferase activity was detected with a Luciferase
Reporter Assay System (Promega, USA) according to the
manufacturer’s protocol. The luciferase backbone
lentivirus was used for insertion of Nanog promoter
regions with different transcriptional start site (TSS)
lengths (− 500 bp, − 1000 bp, − 1500 bp). Three days
after transfection, the cells were starved in FBS-free
medium for 24 h and then treated with vehicle or DHT
with or without ASC-J9 for another 24 h. To examine
the effect of androgen on the Nanog gene promoter, the
activities of different sections of the Nanog gene were
tested by stimulating and (or) suppressing androgen
signaling. We used constructed pGL3.0 firefly luciferase
gene reporters and lentivirus vectors with three different
regions of the Nanog gene.
iCELLigence
Cell proliferation in vitro was investigated with iCELLi-
gence software (ACEA Biosciences, USA). We sorted
and treated the GFP (+) and GFP (−) cell groups treated
with DHT or DHT +ASC-J9. An equal number of GFP
(+)/GFP (−) cells (5 × 103 cells) were seeded. GFP
(+)/GFP (−) groups were divided into two subgroups:
10 nM DHT and 10 nM DHT plus 5 μM ASC-J9. The
compounds were added to each well. Then, the cells
were cultured and monitored for 25–37 h. All experi-
ments were performed in triplicate.
Transwell assay
For Transwell assays, 6.5-mm chambers with 8-μm
pores (Corning, USA) were placed into 24-well plates
and used to assess the migration of SKOV3 + 5 and
A2780 + 20 GFP (+) or (−) cells. Cells were grown in
Transwell chambers without Matrigel and treated with
either DMSO, DHT or DHT +ASC-J9. An equal
number of cells (5 × 104 cells in 100 μl of serum-free
modified 1640 medium) were seeded into the upper
chambers of polycarbonate Transwell filters. A total of
600 μl of modified 1640 medium containing 10% FBS
was added to the bottom of the chambers. After incuba-
tion for 16 h, migrated cells were fixed with methanol
and stained with hematoxylin and eosin. Images of four
random fields in each membrane were captured with a
microscope. For analysis, the cells number in four fields
was calculated at 40× magnification (images shown in
Additional file 1: Figure S6).
Sphere formation assay
For GFP (+)/(−) cell identification, SKOV3 + 5 or
A2780 + 20 single GFP(+) or (−) cells were sorted via
FACS. Then, cells were seeded into 96-well ultralow
attachment plates (Corning). The medium comprised
DMEM/F12 (Invitrogen, USA), 2% B27 (Prepro Tech,
USA), 20 ng/ml EGF (Prepro Tech, USA), 20 ng/ml
bFGF, and 4 μg/ml heparin. The cells were treated for
14 days before analysis.
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Colony formation assay
Colony formation assays were performed in 24-well
plates. Cells were sorted and cultured in DMEM supple-
mented with 10% FBS for 14 days. In terms of hormone
treatment, after seeding for 24 h, the medium was chan-
ged to DMEM with low FBS (2%), with or without the
indicated reagents (DHT, DHT +ASC-J9 or DMSO).
The medium was replaced every two days, and the cells
were treated for 14 days. On the final day, the cells were
fixed with 4% paraformaldehyde and stained with freshly
prepared crystal violet for 20 min. Colony formation was
observed under a microscope (Nikon, Japan).
Immunohistochemistry
Immunohistochemical staining was performed using a
conventional protocol. In brief, the tumor tissues were
fixed in 4% paraformaldehyde immediately after removal
from the mice. Then, samples were embedded in paraf-
fin, sectioned, and immunostained. The sections were
incubated with anti-AR (Abcam, UK) or anti-Nanog
(Abcam, UK) primary antibodies at 4 °C for 16 h and
secondary antibodies (DaKo, DEN) at 37 °C for 0.5 h.
Finally, sections were counterstained with Mayer’s
hematoxylin and mounted. Sections were visualized, and
images were captured with an Olympus camera.
Xenograft study
All animal experiments were performed in accordance
with the “Guide for the Care and Use of Laboratory
Animals” and were approved by the Animal Ethics
Committee of the Third Military Medical University. All
mice were maintained in pathogen-free conditions.
Nanog A2780 + 20 GFP (+) or GFP (−) cells (5 × 104)
were suspended in PBS and mixed with Matrigel
(volume ratio 1:1) (BD Biosciences, USA). Then, 200 μl
of this mixture was injected subcutaneously into the
dorsal surface of 5-week-old female nude mice. Five
mice with 2 transplant sites each were used for the
experiment. All mice were sacrificed after 30 days, and
the tumor masses were measured. Moreover, to further
validate the stemness of the GFP (+) cells and the effect
of the hormone treatment in vivo, we constructed an-
other animal model by injecting 5 × 103 A2780 + 20 cells
into the dorsal surface of 12 female nude mice. When
the xenografts reached approximately 180 mm3, the
animals were divided into two groups: androgen
treatment and anti-androgen treatment groups. The
(clinically used) drugs were as follows: the androgen was
a testosterone undecanoate soft capsule (N.V. Organon,
NL), and the anti-androgen was a bicalutamide tablet
(AstraZeneca, UK). Intragastric drug administration was
performed every three days, and the sizes of the xeno-
grafts were measured. The doses of the androgen and
anti-androgen (according to the clinical reference dose)
were 6 mg/kg and 8.4 mg/kg, respectively. After 9 treat-
ments, the mice were sacrificed, and the tumors were
imaged with an in vivo imaging system (PerkinElmer,
USA).
Statistical analyses
Each experiment was performed in triplicate. Statistical
tests were performed using SPSS 17.0 and GraphPad
Prism 5.0 (GraphPad Software). In addition, one-way
ANOVA or a t-test was performed with normalization
to obtain P-values. The criteria for statistical significance
were P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). Rela-
tive analysis of AR and Nanog expression was calculated
with Pearson’s correlation coefficient using the formula
in SPSS 17.0.
Results
AR is overexpressed and correlated with Nanog expression
in ovarian cancer
To examine AR expression in ovarian cancer, we
compared the AR protein expression levels in ovarian
cancer tissues (n = 7) with those in normal ovarian tis-
sues (n = 7) with a western blot analysis. Our results
showed that the AR expression levels were significantly
higher in ovarian cancer than in normal ovarian tissues
(Fig. 1a and b). We further confirmed AR overexpression
in ovarian cancer via immunohistochemistry. Compared
with the negative signals in the normal ovarian tissues,
AR was strongly expressed in the cytoplasm and nucleus
of ovarian tumor cells (Fig. 1d). Next, we examined the
Nanog protein expression levels in the same set of
samples by western blot analysis. Our results showed
that the Nanog expression levels were significantly
higher in the ovarian tumor tissues than in the normal
ovarian tissues (Fig. 1a and b). Moreover, using Pearson’s
correlation analysis, we found that the correlation coeffi-
cient (R) between AR and Nanog was 0.61 (Fig. 1c), indi-
cating that AR and Nanog expression was correlated in
ovarian tumor tissues.
Labeling of endogenous Nanog with GFP in ovarian
cancer cells with the CRISPR/Cas9 system
To examine how endogenous Nanog expression changes
under different conditions, we used the CRISPR/Cas9
system to label Nanog with GFP. Using the CRISPR/
Cas9 system, we constructed PX330 Nanog-gRNA that
targeted a specific site in front of the Nanog termination
codon, and we established a Nanog-2A-GFP recombin-
ation homologous arm. We expected that the GFP fluor-
escence would represent Nanog expression in ovarian
cancer cells directly and accurately. Nanog-gRNA was
then inserted into the PX330 plasmid, and the Nanog
gene target CRISPR/Cas9 vector, PX330-Nanog-gRNA,
was generated (Fig. 2a). We co-transfected A2780 or
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SKOV3 ovarian cancer cell lines with the PX330-Nanog-
gRNA vector and the Nanog-2A-GFP donor plasmid to
generate Nanog-labeled ovarian cancer cells. Since the
recombinant plasmid Nanog-2A-GFP had no promoter,
the transcriptional activity of GFP appeared only when
the restructured coding area was correct (Fig. 2a). Thus,
the inserted endogenous Nanog GFP marker could
distinguish the restructured and non-restructured cells.
We obtained several single clones with the correct
CRISPR/Cas9 insertion, and these clones were subse-
quently verified by PCR, restriction enzyme digestion,
and Sanger sequencing (Fig. 2b-d). We randomly chose
two independent clones, namely, A2780 clone 20
(A2780 + 20) and SKOV3 clone 5 (SKOV3 + 5), for sub-
sequent experiments.
AR and Nanog co-localization in ovarian cancer cells
GFP (+) and (−) cells from the two clones were sorted
by FACS. We then determined the Nanog expression
levels in the GFP (+) and (−) cells of the two clones. As
predicted, Nanog expression was significantly higher in
the GFP (+) cells than in the GFP (−) cells at both the
mRNA and protein levels (Fig. 3a and b). To investigate
possible relationships between AR and Nanog in ovarian
cancer, AR expression in the GFP (+) and (−) cells of the
two clones was examined. Our results showed that AR
expression was significantly higher in the GFP (+) cells
than in the GFP (−) cells at both the mRNA and protein
levels (Fig. 3c and d). These results suggested that AR
expression followed a trend consistent with Nanog
expression in ovarian cancer cells. Moreover, we investi-
gated whether the AR protein co-localized with the
Nanog protein in ovarian cancer cells. AR and Nanog
expression signals in the GFP (+) ovarian cancer cells
were detected via confocal laser scanning microscopy.
The results showed that the GFP signals were co-
localized with the AR expression signals in the GFP (+)
cells (Fig. 3e), indicating that GFP fluorescence accur-
ately represented Nanog expression in the labeled cells.
Furthermore, we found that the GFP signals were co-
Fig. 1 AR expression in ovarian tumors and corresponding Nanog gene expression. a) Western blot analysis of AR and Nanog expression in 7
ovarian tumors and 7 normal ovaries. b) AR and Nanog expression in ovarian tumors were higher than that in normal ovaries. Quality control
software (Bio-Rad) was used to obtain the quantitative value relative to GAPDH. c) Correlation analysis of the AR and Nanog expression levels,
indicating a correlation coefficient (R) of 0.61. d) Immunohistochemistry staining of AR expression in ovarian tumors and normal ovaries.
In ovarian tumors, the positive (brown) staining is obvious. Bar value: 100 μM. T: ovarian tumor. N: normal ovaries. GAPDH: loading control.
** P < 0.01; *** P < 0.001
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localized with the AR expression signals in the GFP (+)
ovarian cancer cells (Fig. 3f ). Therefore, our results indi-
cated that AR and Nanog are co-localized in ovarian
cancer cells. Moreover, a possible reciprocal action is
predicted to exist.
Androgen induces Nanog promoter activity in ovarian
cancer cells through AR
Androgen up-regulates Nanog expression, and AR binds
directly to AREs in the promoter region of Nanog in





Fig. 2 Construction and verification of an endogenous GFP Nanog marker. a) Map of the CRISPR/Cas9 target site on exon 4 of the Nanog gene,
the gRNA sequence. b) The PCR GFP products of the A2780 + 20 and SKOV3 + 5 GFP (+) clonal cells (agarose gel electrophoresis). The negative
control is the non-targeted A2780 cells without GFP. c) Enzyme digestion of PCR products from A2780 + 20 and SKOV3 + 5 monoclonal cells.
d) The Sanger sequencing results: the bases labeled in blue represent the end of the Nanog exon 4 and the first of the 2A joint sequences in
A2780 + 20 and SKOV3 + 5 monoclonal cells
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activates Nanog transcription in ovarian cancer cells, we
performed the following promoter activity luciferase
assay. We cloned three different regions of the Nanog
promoter (TSS + 1 to − 500, TSS -500 to − 1000, and
TSS -1000 to − 1500) into lentivirus vectors (named
Lvpnanog-500, Lvpanog-1000, and Lvpnanog-1500,
respectively). Each of the cloned regions of the Nanog
promoter contained AREs. Using a pGL3.0 firefly lucifer-
ase gene reporter assay, we first used the lentivirus vectors
containing the pGL3.0 firefly luciferase gene to transduce
ovarian cancer cells (A2780 + 20 and SKOV3 + 5). To
examine the effects of androgen on Nanog promoter ac-
tivity in ovarian cancer cells, we treated cells with DHT or
DMSO (as the vehicle control). Compared with the
vehicle control, the DHT treatment significantly in-
creased Nanog promoter activity in ovarian cancer
cells (Fig. 4a and b). To confirm whether androgen-
induced Nanog promoter activity was conducted
through AR, we treated cells with dimethylcurcumin
(ASC-J9), a selective enhancer of AR degradation.
Our results showed that treatment with ASC-J9 di-
minished the effect of DHT on induction of Nanog pro-
moter activity in ovarian cancer cells (Fig. 4a and b). Since
treatment with DHT or ASC-J9 did not induce ovarian
cancer cell death (Fig. 4c), our results indicate that andro-
gen induced Nanog gene promoter activity in ovarian can-
cer cells through the AR signaling axis.
AR signaling axis promotes ovarian cancer cell
proliferation in vitro via the Nanog pathway
As mentioned above, we confirmed that the dose of
DHT/DMSO/ASC-J9 did not decrease cell viability.
Therefore, cell growth comparisons of the DMSO-
treated GFP (+) or GFP (−) cells were unnecessary. To
examine whether the AR signaling axis triggered the
proliferation of Nanog GFP (+) and GFP (−) cells, cell
growth indices were determined using iCELLigence soft-
ware. As expected, both A2780 + 20 and SKOV3 + 5
GFP (+) cells treated with DHT quickly exhibited in-
creased cell growth compared with GFP (−) cell growth
Fig. 3 AR and Nanog co-exist in GFP Nanog (+) monoclonal cells. a and b) Nanog mRNA and protein expression in the Nanog GFP (+)/(−) cells
of the A2780 and SKOV3 cell lines was examined by RT-qPCR and western blot, respectively. c and d) The mRNA and protein expression of both
Nanog and AR in the Nanog GFP (+)/(−) cells of the A2780 and SKOV3 cell lines was also examined. e and f) Localization of Nanog and AR
expression in Nanog GFP (+)/(−) cells determined by immunofluorescence staining; **P < 0.01; ***P < 0.001. GAPDH: loading control. Bar value:
100 μM. White arrow: double-positive cell. Red arrow: double-negative cell
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within 24 h (P < 0.01; Fig. 5a and b). For the DHT +
ASC-J9 group, the addition of ASC-J9 attenuated the
DHT effect and reduced GFP (+) cell proliferation
within 36 h (Fig. 5c and d). Our results demonstrate that
DHT increased cell proliferation by regulating Nanog.
The results also suggested that anti-androgen (ASC-J9)
might block the effect of the Nanog pathway.
AR signaling axis increases migratory ability through
Nanog activation
To determine whether the AR signaling axis promotes cell
migration through Nanog, we examined the effect of
DHT or ASC-J9 on Nanog GFP (+) and GFP (−) cells.
A2780 + 20 and SKOV3 + 5 cell lines showed difference
between Nanog GFP (+) and GFP (−) cells (Fig. 6a and b).
Our results indicated that DHT-treated Nanog GFP (+)
migrated more than cells treated with DMSO or DHT+
ASC-J9 (Fig. 6b and d). Meanwhile, the migratory ability
in the Nanog GFP (+) group was higher than that in the
Nanog GFP (−) group (Fig. 6e and f). Taken together,
these data demonstrate that the DHT-induced AR signal-
ing axis stimulates migration through Nanog in vitro.
Protein expression of other stem cell genes exhibits the
same trend as Nanog
We hypothesized that Nanog protein expression was
consistent with that of other stem cell genes in GFP (+)
cells. Hence, we also examined the protein expression of
other stem cell markers, namely, Oct4 and Sox2. Based
on western blot analysis, both Oct4 and Sox2 expression
in GFP-positive cells exhibited the same trend as Nanog
expression (Fig. 7a and b). Moreover, we found that
Oct4 and Sox2 expression increased under DHT treat-
ment, while there were no changes under DHT + ASC-
Fig. 4 The AR signaling axis increases Nanog transcriptional activity. a and b) Promoter activities of different regions of the Nanog promoter,
namely, TSS + 1~ − 500 bp, − 500~ − 1000 bp, and − 1000~ − 1500 bp, under androgen treatment in A2780 + 20 and SKOV3 + 5 cells determined
using firefly luciferase reporter assays. c) Cell death and viability were tested with MTS assays. No differences were evident among the groups.
Control: no treatment. Vehicle: DMSO; DHT: 10 nM; ASC-J9: 5 μM. *P < 0.05; **P < 0.01
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J9 treatment (Fig. 7c and d). From these results, we sus-
pected that the AR signaling axis might promote and
maintain the cell stemness phenotype.
Androgen induces Nanog-mediated stemness properties
and tumorgenicity in ovarian cancer cells
To determine whether Nanog expression affected the
stemness properties of ovarian cancer cells, we per-
formed sphere formation assays using the monoclonal
GFP (+)/(−) ovarian cancer cell lines (A2780 + 20 and
SKOV3 + 5). Our results showed that the sphere forma-
tion abilities of the GFP (+) cell lines were significantly
higher than those of the GFP (−) cell lines (Fig. 8a).
Next, to examine whether Nanog expression affected
ovarian cancer cell tumorigenicity, we performed colony
formation assays using the monoclonal GFP (+)/(−)
ovarian cancer cell lines (A2780 + 20 and SKOV3 + 5).
Our results showed that the colony formation of the
GFP (+) cell lines was significantly higher than that of
the GFP (−) cell lines (Fig. 8b). These results suggested
that the high Nanog expression levels in the GFP (+) cell
lines promoted the stemness properties and tumorigen-
icity of ovarian cancer cells.
To investigate whether the Nanog-regulated stemness
properties and tumorigenicity of the ovarian cancer cells
were regulated by the AR signaling axis, we treated the
A2780 + 20 and SKOV3 + 5 cell lines with DHT and
performed sphere and colony formation assays. Our re-
sults showed that DHT treatment enhanced the sphere
and colony formation of the ovarian cancer cell lines
compared with the vehicle control (Fig. 8c and d). After
treatment of the ovarian cancer cell lines with the AR
inhibitor ASC-J9, the DHT-mediated sphere and colony
formation of the ovarian cancer cell lines was diminished
(Fig. 8c and d). Thus, these results suggest that androgen
induces Nanog-mediated stemness properties and
tumorgenicity in ovarian cancer cells through AR.
Nanog interaction with AR promotes ovarian
tumorigenicity in vivo
To investigate the effect of Nanog on ovarian tumori-
genicity in vivo, GFP (+) and (−) monoclonal ovarian
cancer cells (A2780 + 20) were inoculated subcutane-
ously into female nude mice to generate a xenograft
model of human ovarian cancer. First, we established
the animal model without hormone treatment. Our re-
sults showed that tumor xenografts formed from the
GFP (+) ovarian cancer cells were significantly larger
than those formed from the GFP (−) ovarian cancer cells
(Fig. 9a). This result suggests that high Nanog expression
levels promote ovarian cancer tumorigenicity in vivo. The
AR and Nanog expression levels were higher in the GFP
(+) xenografts than in the GFP (−) xenografts, determined
via IHC (Fig. 9b and d). Furthermore, to explore the effect
Fig. 5 DHT-induced Nanog GFP (+) cell proliferation according to iCELLigence. a and b) The indices of the A2780 + 20 and SKOV3 + 5 GFP (+)
cells treated with DHT increased more quickly than those of the GFP (−) cells within 24 h. One hour was used for normalization. The maximum
cell index of the GFP (+) cells was significantly different from that of the GFP (−) cells. c and d) There were no obvious differences in the growth
of the A2780 + 20 and SKOV3 + 5 GFP (+)/GFP (−) cells during treatment with DHT plus ASC-J9. The growth curves terminated within 37 h. The
cell indices showed no differences. **P < 0.01; ***P < 0.001
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of hormone treatment in vivo, 12 mice were injected with
5 × 103 A2780 + 20 GFP-positive cells to establish animal
models; all mice developed xenograft tumors, but one
mouse died before hormone treatment. The tumor
volume in the androgen treatment group increased faster
than that in the anti-androgen group. (Fig. 9f). Photo-
graphs were captured by an in vivo imaging system after
the mice were sacrificed, and fluorescence in the anti-
androgen treatment group was weaker than that in the
androgen treatment group (Fig. 9e). Taken together, our
results suggest that Nanog induces stemness properties
and promotes ovarian tumorigenicity by interacting with
AR in vivo.
Discussion
In this study, we have demonstrated that the AR signal-
ing axis induces Nanog-mediated stemness properties
and tumorgenicity in ovarian cancer. To the best of our
knowledge, few studies have addressed the relationship
between AR and Nanog in ovarian cancer or the regula-
tion of OCSCs. Several studies have reported that AR
expression is higher in ovarian cancer than in normal
ovaries [30]. Hence, we hypothesized that the AR signal-
ing axis is associated with ovarian cancer. Our study
began by investigating the expression levels of AR and
Nanog in the same cohort of samples via IHC and west-
ern blot analysis (Fig. 1). We determined that the AR
and Nanog expression levels in ovarian tumors were
higher than those in the ovaries (Fig. 1a-c). AR was
expressed strongly in the cytoplasm and nucleus of ovar-
ian tumor cells (Fig. 1d). We wondered whether a direct
relationship existed between AR and Nanog in ovarian
cancer. Moreover, we examined whether this signaling
axis was consequently involved in OCSC regulation.
Therefore, endogenous Nanog labeling in ovarian can-





Fig. 6 Migratory tendency of GFP (+)/GFP (−) cells when treated with different hormone drugs. a and b) The number of migratory cells increased
in the DHT groups of the A2780 + 20 and SKOV3 + 5 GFP (+)/GFP (−) cell lines. c and d) Notably, when treated with DHT, the number of GFP (+)
migratory cells increased markedly compared with DMSO or DHT + ASC-J9; e and f) The number of migratory in A2780 + 20 and SKOV3 + 5
Nanog GFP (+) cells were also higher than that of the Nanog GFP (−) cells. For analysis, the cells number in four fields was calculated at 40×
magnification. Bar: 100 μM. DHT: 10 nM, and ASC-J9: 5 μM. **P < 0.01; ***P < 0.001
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and possible mechanisms of the two genes in ovarian
cancer. We generated several single clones with the
correct GFP marker (A2780 + 20 and SKOV3 + 5) by
using the CRISPR/Cas9 insertion system and then
compared the GFP (+) and GFP (−) cells under various
conditions (Fig. 2). CRISPR/Cas9 technology was used
to construct a stable GFP marker for subsequent experi-
ments that could avoid the disadvantages of other
methods, such as GFP degradation. We also confirmed
that AR and Nanog were co-localized in ovarian cancer
cells (Fig. 3). Nanog activity was promoted by AR, which
was consistent with the results of a study by Kregel et al.
[27]. Meanwhile, crystallographic data have shown that
AR contains an additional interface that stabilizes the
AR dimer/ARE complex. In contrast, the dimerization
strengths of other steroid receptors would not be suffi-
cient to retain stable binding to selective AREs [31]. We
interpreted these data as strong evidence confirming this
pathway. In this study, using luciferase assays, we
showed that the AR signaling axis induced Nanog pro-
moter activity in ovarian cancer cells (Fig. 4). Ovarian
cancer cells treated with different hormones were used
to confirm the effect of the AR signaling axis. Moreover,
to explore the possible regulation of AR and Nanog in
ovarian cancer cells, the proliferation and migration abil-
ities of single-clone Nanog GFP (+) cells with or without
hormone treatments were examined (Figs. 5-6). DHT
distinctly increased GFP (+) cell proliferation and migra-
tion. Under DHT + ASC-J9 treatment, no differences
were evident between the Nanog GFP (+) and GFP (−)
cells. Additionally, our previous study suggested that
GFP (−) cells treated with DHT could undergo dediffer-
entiation via transformation from non-CSCs to stem-like
cells [29]. For this reason, DHT not only promoted the
migratory ability of the GFP (+) cells but also affected
GFP (−) cells in this experiment. We also examined the
Oct4 and Sox2 protein expression levels. Interestingly,
Oct4 and Sox2 levels increased along with Nanog ex-
pression when cells were treated with DHT (Fig. 7). In
addition, DHT clearly enhanced ovarian cancer cell
sphere and colony formation compared with the vehicle
control and DHT/ASC-J9 treatment (Fig. 8). Thus,
our in vitro studies showed that androgen induces
Nanog-mediated stemness properties and tumorgeni-
city in ovarian cancer cells directly through AR. Our
in vivo results suggest that Nanog induces stemness
properties and promotes ovarian tumorigenicity by
interacting with AR (Fig. 8). This study demonstrates
that the AR signaling axis interaction with Nanog in-
duces and maintains OCSC stemness by activating
the Nanog promoter. We presume that an interaction
effect is present between Nanog and AR and suggest
that the AR-Nanog signaling pathway participates in
OCSC regulation. Even though ovarian cancer has a
complex network and microenvironment, this
phenomenon may mean that increased AR activity is
related to a high risk of this disease. However, the
evidence is not sufficient to demonstrate the mechan-
ism of the AR-Nanog signaling axis in patients.
Nevertheless, we suggest that the AR-Nanog signaling
axis participates in OCSC regulation and may be a
prognostic bio-marker.
Fig. 7 Protein expression of other stem cell genes exhibits the same tendency as Nanog. a and b) Oct4 and Sox2 expression increased in the
GFP (+) cells compared with the GFP (−) cells according to western blot analysis. c and d) Oct4 and Sox2 expression in the GFP (+) cells clearly
increased under DHT treatment compared with ASC-J9 treatment based on western blot analysis, which was also consistent with the Nanog
expression trend
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We present compelling evidence to show that Nanog
plays a vital role in malignant diseases and is correlated
with the clonogenic growth, tumorigenicity and invasive-
ness of cancer cells [11, 32, 33]. Hence, Nanog appears to
function as a cooperating or potentiating pro-tumorigenic
molecule in the appropriate context [34]. The highlight of
our study is our cell model, which was successfully built
with CRISPR/Cas9 technology, and the Nanog GFP
Fig. 8 AR signaling axis enhances the stemness characteristics of ovarian cancer cells. a) Sphere formation assays of the monoclonal GFP (+)/GFP
(−) cells of the SKPV3 + 5 and A2780 + 20 cell lines. The sphere formation abilities of the GFP (+) cell lines were significantly stronger than those
of the GFP (−) cell lines. Bar: 200 μM. b) Colony formation assays of the monoclonal GFP (+)/GFP (−) cells of the SKPV3 + 5 and A2780 + 20 cell
lines. The clonal efficiency of the GFP (+) cells was higher than that of the GFP (−) cells. Bar: 200 μM. c and d) Androgen or inhibitor treatment in
SKPV3 + 5 and A2780 + 20 GFP (+) cells. Sphere and colony formation were enhanced when DHT was added, while ASC-J9 decreased this effect.
DMSO was used as the vehicle control. DHT: 10 nM, and ASC-J9: 5 μM; Bar: 100 μM. *P < 0.05, **P < 0.01, and ***P < 0.001
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marker can be used to monitor and study authentic CSCs
or pluripotency. The 2A-tdTomato sequence can report-
edly be inserted by homogenous recombination to replace
the stop codon of the porcine gene. Thus, fluorescence
can accurately show activation of the endogenous gene
through CRISPR/Cas9 [35]. These results indicate that the
knock-in reporter system can be used to efficiently moni-
tor the pluripotency status of cells. Using the CRISPR/
Cas9 knock-in reporter system, we can monitor and inves-
tigate the complicated functions and regulation of genes
more directly. Since the conditions of ovarian cancer cells
are complex, other cell lines and networks require further
elaboration.
Previous studies have not demonstrated efficient
effects when anti-androgen is used to treat patients, but
we should still consider the effects and design more ani-
mal studies to investigate this process [36]. In the future,
we hope to identify new anti-androgen approaches to
eliminate OCSCs or to inhibit cancer cell growth in






Fig. 9 The tumorigenicity of A2780 + 20 GFP (+) cells in vivo. a) The xenografts produced by the A2780 + 20 GFP (+) cells were larger than those
produced by the GFP (−) cells; 5 × 104 cells were injected. b-d) AR expression in A2780 + 20 GFP (+) tumors was stronger than that in GFP (−)
tumors. Similarly, Nanog expression was increased in A2780 + 20 GFP (+) tumors. e and f) For the in vivo hormone treatment groups, 12 mice
(injected with 5 × 103 A2780 + 20 GFP-positive cells) underwent xenografting, but one died before treatment. The tumor volume in the androgen
treatment group increased more quickly and was greater than that in the anti-androgen group (P < 0.05). Fluorescence was weak after the anti-
androgen treatment compared to that with androgen treatment. Photographs were captured with an in vivo imaging system
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Conclusion
In conclusion, this study demonstrates that AR functions
as an oncogene by promoting Nanog expression in ovar-
ian cancer cells, and the interaction of Nanog with the
AR signaling axis might induce or contribute to OCSC
regulation. Androgen might promote stemness charac-
teristics in ovarian cancer cells by activating the Nanog
promoter. These findings may provide a new under-
standing of OCSC regulation from a hormone perspec-
tive and lead to the reevaluation of stem cell therapy for
ovarian cancer.
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